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Backgroud: Activation of the protein kinase B/mammalian target of rapamycin (AKT/mTOR) pathway has been
demonstrated to be involved in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated tumorigenesis in
anaplastic large cell lymphoma (ALCL) and correlated with unfavorable outcome in certain types of other cancers.
However, the prognostic value of AKT/mTOR activation in ALCL remains to be fully elucidated. In the present study,
we aim to address this question from a clinical perspective by comparing the expressions of the AKT/mTOR
signaling molecules in ALCL patients and exploring the therapeutic significance of targeting the AKT/mTOR
pathway in ALCL.
Methods: A cohort of 103 patients with ALCL was enrolled in the study. Expression of ALK fusion proteins and the
AKT/mTOR signaling phosphoproteins was studied by immunohistochemical (IHC) staining. The pathogenic role of
ALK fusion proteins and the therapeutic significance of targeting the ATK/mTOR signaling pathway were further
investigated in vitro study with an ALK + ALCL cell line and the NPM-ALK transformed BaF3 cells.
Results: ALK expression was detected in 60% of ALCLs, of which 79% exhibited the presence of NPM-ALK, whereas
the remaining 21% expressed variant-ALK fusions. Phosphorylation of AKT, mTOR, 4E-binding protein-1 (4E-BP1), and
70 kDa ribosomal protein S6 kinase polypeptide 1 (p70S6K1) was detected in 76%, 80%, 91%, and 93% of ALCL
patients, respectively. Both phospho-AKT (p-AKT) and p-mTOR were correlated to ALK expression, and p-mTOR was
closely correlated to p-AKT. Both p-4E-BP1 and p-p70S6K1 were correlated to p-mTOR, but were not correlated to the
expression of ALK and p-AKT. Clinically, ALK + ALCL occurred more commonly in younger patients, and ALK + ALCL
patients had a much better prognosis than ALK-ALCL cases. However, expression of p-AKT, p-mTOR, p-4E-BP1, or
p-p70S6K1 did not have an impact on the clinical outcome. Overexpression of NPM-ALK in a nonmalignant murine
pro-B lymphoid cell line, BaF3, induced the cells to become cytokine-independent and resistant to glucocorticoids
(GCs). Targeting AKT/mTOR inhibited growth and triggered the apoptotic cell death of ALK + ALCL cells and NPM-ALK
transformed BaF3 cells, and also reversed GC resistance induced by overexpression of NPM-ALK.
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Conclusions: Overexpression of ALK due to chromosomal translocations is seen in the majority of ALCL patients and
endows them with a much better prognosis. The AKT/mTOR signaling pathway is highly activated in ALK + ALCL
patients and targeting the AKT/mTOR signaling pathway might confer a great therapeutic potential in ALCL.
Keywords: Anaplastic large cell lymphoma (ALCL), Anaplastic lymphoma kinase (ALK), AKT, mTOR, 4E-BP1, p-70S6K1,
PrognosisBackground
Anaplastic large cell lymphoma (ALCL) is an aggressive
form of non-Hodgkin’s lymphoma (NHL) of T/null lineage.
It constitutes approximately 5% of all human NHL, but
accounts for as many as 30% to 40% of pediatric large cell
lymphomas [1]. Roughly 50 to 70% of ALCL patients carry
characteristic chromosomal translocations involving the
anaplastic lymphoma kinase (ALK) gene on chromosome
2p23, resulting in ALK overexpression due to the abnormal
fusion of ALK with other genes [2]. The most common of
these aberrations is the t(2;5)(p23;q35), which leads to the
expression of the chimeric protein nucleophosmin-ALK
(NPM-ALK). The others express variant fusions that, like
NPM-ALK, involve the entire cytoplasmic portion of ALK,
but fuse to other N-terminal partners, like tropomyosin 3
(TPM3) or 5-aminoimidazole-4-carboxamide ribonucleo-
tide formyltransferase/IMP cyclohydrolase (ATIC) [3-5]. So
far, at least 15 variant-ALK fusion genes have been identi-
fied in both hematopoietic malignancies, such as ALCL and
diffuse large B cell lymphoma, and non-hematopoietic
neoplasms, including inflammatory myofibroblastic tumor,
esophagus cancer, and non-small cell lung cancer [6-11].
ALK immunostainning of NPM-ALK-positive ALCL cases
shows a characteristic cytoplasmic and nuclear distribu-
tion of the chimeric ALK protein that is due to hetero-
oligomerization of NPM-ALK and normal NPM, a
phosphoprotein that normally shuttles ribonucleopro-
teins between the cytoplasm and nucleus, but can aber-
rantly transport NPM-ALK to the nucleus [12]; whereas
patients with the variant-ALK fusion proteins demonstrate
cytoplasmic staining only [13,14]. In ALCL, ALK expres-
sion has a strong clinical prognostic significance. Com-
pared with ALK negative (ALK-) ALCL, ALK positive
(ALK+) ALCL occurs more frequently in younger patients
who respond well to chemotherapy and have a favorable
clinical outcome [1,15-19].
The mechanisms of cell transformation mediated by
the ALK oncoprotein are only partially understood [5,20,21].
However, the NPM-ALK-induced activation of mammalian
target of rapamycin (mTOR), either transduced through
the mitogen-induced extracellular kinase (MEK)/extracel-
lular signal-regulated kinase (ERK) signaling pathway, or
to a much less degree, through the phosphatidylinositol
3-kinase/protein kinase B (PI3K/AKT) pathway has been
shown to contribute to the tumorigenesis of ALCL [22,23].In ALK+ALCL cell lines and tumors, the mTOR signaling
proteins, including mTOR, eukaryotic initiation factor 4E-
binding protein-1 (4E-BP1), and the 70 kDa ribosomal pro-
tein S6 kinase polypeptide 1 (p70S6K1) kinase are highly
phosphorylated [23]. Inhibition of mTOR with rapamycin
or silencing mTOR gene product expression using mTOR-
specific small interfering RNAs decreased phosphorylation
of the mTOR signaling proteins and induced cell cycle
arrest and apoptosis in ALK + ALCL cells, indicating
that blockage of the mTOR signaling pathway repre-
sents a potential therapeutic strategy in ALK + ALCL
[22,23]. Nevertheless, there is little evidence demon-
strating the clinical prognostic value of the mTOR path-
way activation in ALCL. In this relatively large case
study, we showed that the AKT/mTOR pathway was
highly activated in ALK + ALCLs compared with ALK-
cases. Phosphorylation of AKT and mTOR was corre-
lated to the expression of ALK, suggesting an activated
ALK/AKT/mTOR pathway in ALK +ALCL; and this acti-
vation pathway was further confirmed by overexpression
of NPM-ALK in the nonmalignant murine pro-B lymph-
oid cell line, BaF3. In contrast to ALK expression, expres-
sion of p-AKT, p-mTOR, p-4E-BP1, or p-p70S6K1 did not
have any prognostic significance in ALCL; however,
in vitro studies indicated that targeting the hyperactivated
AKT/mTOR pathway effectively inhibited cell growth,
triggered apoptosis, and reversed glucocorticoid (GC) re-
sistance, suggesting an attractive therapeutic potential of
AKT/mTOR inhibitors in ALCL.Methods
Tumor samples
The tumor specimens were obtained from 103 patients
with ALCL who underwent biopsy between January
2005 and October 2012 at the Department of Pathology,
West China Hospital of Sichuan University, or the Depart-
ment of Pathology, Shanghai Children’s Medical Center of
Shanghai Jiaotong University. None of the patients had re-
ceived any treatment before surgery. Tumor diagnosis was
based on histological examination of tissue specimens
obtained by biopsy and based on the criteria of the World
Health Organization Classification. Written informed con-
sent was obtained prior to sample collection from all pa-
tients or their parents if the patients were young children.
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Immunohistochemical (IHC) studies
Rabbit polyclonal antibodies specific for Thr308p-AKT
(p-AKT), Ser2448p-mTOR (p-mTOR), Thr70p-4E-BP1
(p-4E-BP1), and Thr421p-p70S6K1 (p-p70S6K1) (Cell
Signaling Technology, Beverly, MA) were used. ALK ex-
pression was assessed initially by using rabbit polycloncal
antibody ALK11 (a kind gift from Dr. Stephan W. Morris,
St. Jude Children’s Research Hospital) and further con-
firmed by the mouse monoclonal antibody ALK-1 (Dako
Cytomation, Carpinteria, CA) to exclude false positivity.
IHC staining was performed to assess protein expression
in formalin-fixed, paraffin embedded samples by the 2-
step Envision procedure using a DAKO Autostainer
(Dakopatts, Copenhagen, Denmark). The sections (6 μm)
were de-paraffinized in xylene, dehydrated through a
graded series of alcohol, and immersed for 15 min in
phosphate-buffered saline (PBS). For antigen retrieval, sec-
tions were boiled in a pressure cooker for 4 min in 0.01 M
citrate buffer (pH 6.0). Endogenous peroxidase activityFigure 1 Histology and immunohistochemistry (IHC) of ALCL tumor s
classic type of ALCL. The tumor cells are large with abundant cytoplasm an
pleomorphic nucleus of kidney-shape. (B) ALCL of small cell type. The tum
nucleoli. (C to H) IHC staining of ALCL tumor samples (EnVision staining). E
assessed. (C, D) IHC staining with ALK1 antibody. (C) The tumor cells show
cytoplasmic staining only. (E) IHC staining with Thr308p-AKT antibody. The
with Ser2448p-mTOR antibody. The tumor cells show cytoplasmic staining.
cytoplasmic staining. (H) IHC staining with Thr421p-p70S6K antibody. The t
400× magnification.was blocked with 3% hydrogen peroxidase in methanol
(10 min), and non-specific staining was then blocked with
a 20 min incubation with normal horse serum. The sec-
tions were subsequently incubated overnight at 4°C with
primary antibodies (ALK11, ×1000; ALK1, ×100; p-AKT,
×100; p-mTOR, ×100; p-4E-BP1, ×50; p-p70S6K1, ×25) in
a humid chamber, treated for 30 min with a biotinylated
horse secondary antibody against mouse immunoglobu-
lins (ABC Elite; Vector, Burlingame, CA), and then ex-
posed for 5 min to 0.06% diaminobenzidine with 0.01%
hydrogen peroxidase. The sections were lightly counter-
stained with hematoxylin. Controls were performed by
omitting the primary antibodies.
Evaluation of the IHC staining was performed in a
blinded set up regarding the clinical data. Scoring of the
expression was performed semiquantitatively. In brief,
both percentage of stained cells and staining intensity
were evaluated. No staining or weak staining in <10% of
cells was defined as 0, weak staining in at least 10% as 1,
moderate staining in up to 50% as 2 and moderate stain-
ing in >50% of cells and strong staining of any percent-
age of the cells as 3.amples. (A, B) Histology of ALCL tumor samples (HE staining). (A) The
d manifest prominent nucleoli with an eccentrically located and
or cells are small in size, with abundant cytoplasm and prominent
xpression of ALK, p-AKT, p-mTOR, p-4E-BP1, and p-p70S6K eIF4E was
cytoplasmic and nuclear staining. (D) The tumor cells manifest
tumor cells show cytoplasmic and nuclear staining. (F) IHC staining
(G) IHC staining with Thr70p-4E-BP1 antibody. The tumor cells show
umor cells show cytoplasmic staining. All images were captured at
Table 2 Relationship between p-mTOR expression and
activation of ALK and AKT
p-mTOR + (n = 57) p-mTOR- (n = 14) p-value
No. of patients % No. of patients %
ALK (n = 71)
ALK+ 39 of 57 68 5 of 14 36 0.024*
ALK- 18 of 57 32 9 of 14 64
p-AKT (n = 71)
p-AKT+ 47 of 57 83 7 of 14 50 0.011*
p-AKT- 10 of 57 17 7 of 14 50
ALK + (n = 44)
ALK(n + c) 30 of 39 77 3 of 5 60 0.431
ALK(c) 9 of 39 23 2 of 5 40
*Statistically significant value.
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the AKT/mTOR pathway by kinase inhibitors
The murine pro-B cell, BaF3, and an ALK + ALCL cell
line, Karpas 299, were kindly provided by Dr. Stephan
W. Morris (St. Jude Children’s Research Hospital, Memphis,
TN, USA). BaF3 cells (8 × 106) were electroporated with
pcDNA3-NPM-ALK or empty vector (80 μg DNA, 975 μF,
270 V), then selected in IL-3-containing media with
1 mg/mL G418. G418-resistant pools were tested for
NPM-ALK expression, and then seeded at 2 × 105 cells/mL
in growth media with or without IL-3. BaF3/NPM-ALK
and Karpas 299 cells were maintained in RPMI 1640
(Gibco. Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum (FBS; Sigma, St. Louis, MO, USA), 2 mM
L-glutamine (Gibco), and antibiotics (penicillin 100 U/ml
and streptomycin 50 μg/ml) at 37°C in a humidified 5%
CO2 in-air atmosphere. BaF3 cells were cultured in the
same media but with 10 ng/ml IL-3.
NVP-BEZ235 was provided by Novartis Pharma AG
(Basel, Switzerland). For in-vitro use, NVP-BEZ235 was
dissolved in DMSO (Sigma-Aldrich Corp., St. Louis, MO)
to a stock concentration of 100 mmol/L, stored at −20°C,
and further diluted to an appropriate final concentration
in RPMI 1640 at the time of use. Dexamethasone ( Dex,
Sigma, St Louis, MO, USA) was dissolved in ethanol and
used at the concentration of 1 μM. Logarithmically grow-
ing cells were harvested and replated in 96- or 6-well
sterile plastic culture plates (Corning) to which 1 mmol/L
NVP-BEZ235 (NVP group), 1 μM dexamethasone (Dex
group), 1 mmol/L NVP-BEZ235 plus 1 μM dexametha-
sone (NVP +Dex group), or 0.05% DMSO plus 0.1% etha-
nol (Con group) was added. At the end of the incubation,
cells were transferred to sterile centrifuge tubes, pelleted
by centrifugation at 400 g at room temperature for 5 min,
and prepared for analysis as described below.
The MTT assay, used to determine the anti-proliferative
effect of NVP-BEZ235 on cells growing in culture, together
with the apoptosis assay and Western blotting analysis were
performed as described previously (24).Table 1 Relationship between p-AKT expression and ALK
activation in ALCL
p-AKT + (n = 54) p-AKT- (n = 17) p-value
No. of patients % No. of patients %
ALCL (n = 71)
ALK+ 38 of 54 70 6 of 17 35
ALK- 16 of 54 30 11 of 17 65 0.009*
ALK + (n = 44)
ALK (n + c) 29 of 39 74 4 of 5 80
ALK (c) 10 of 39 26 1 of 5 20 0.779
* Statistically significant value.
ALK(n + c) indicates ALK + with both nucleus and cytoplasmic staining; ALK(c),
ALK + with cytoplasmic staining only.Statistical analysis
Statistical analysis was carried out by using the SPSS
15.0 software package. Correlations between various pa-
rameters were calculated by Student’s t-test. Comparison
of the expressions of the mTOR signaling proteins be-
tween ALK + and ALK- ALCL tumors was performed by
chi- squared (χ2) test. The multivariate analysis was
performed by the Cox proportional hazards model to
identify subsets of independent prognostic factors for
overall survival (OS). OS curves were estimated by using
the Kaplan–Meier method and the log–rank test was
used for comparing survival curves of the two groups. A
p value < 0.05 was considered statistically significant.
The analysis included mean values, standard deviation,
standard error, and a 95% confidence interval.
Results
Histology and immunophenotyping of ALCL tumor samples
One hundred and three ALCL tumor samples were his-
tologically divided into 3 types. Eighty cases (78%) wereTable 3 Relationship between expression of p-4E-BP1 and
p-p70S6K and activation of ALK, AKT, and mTOR
p-4E-BP1 p-value p-p70S6K p-value
+ (n = 64) - (n = 7) + (n = 66) - (n = 5)
ALK (n = 71)
ALK+ 40 4 42 2
ALK- 24 3 0.783 24 3 0.119
p-AKT (n = 71)
p-AKT+ 50 4 51 3
p-AKT- 14 3 0.244 15 2 0.408
p-mTOR (n = 71)
p-mTOR+ 56 1 55 2
p-mTOR- 8 6 0.000* 11 3 0.038*
*Statistically significant value.
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were of small cell type (Figure 1B), and the remaining 2
(2%) cases were of lymphohistiocytic type. All tumor
cells strongly expressed CD30. Seventy (68%) were of
T-cell type expressing CD3 and/ or CD45RO and the other
33 were of null cell type expressing no T- or B- lineage
markers. Eighty two (80%) expressed TIA1/Granzyme B
and 62 (60%) cases expressed epithelial membrane antigen
(EMA).Expression of ALK fusion proteins
In the 103 cases of ALCL, 62 (60%) were ALK positive,
and either showed both cytoplasmic and nuclear staining
indicative of the presence of NPM-ALK [49 cases, 79%,
(Figure 1C), or cytoplasmic staining only indicating
variant-ALK fusions 13 cases, 21%, (Figure 1D). Of the
ALK + ALCL cases, the percentages of classic, histolym-
phocytic, and small cell type were 74%, 3%, and 23%,
respectively. In the 41 ALK- ALCL patients, the percent-
ages were 83%, 2%, and 15% respectively. There were no
statistically significant differences of ALK expression be-
tween different histological subtypes of ALCL (χ2 = 0.642,
p > 0.05).Expression of p-AKT and its correlation to ALK expression
Immunostaining was performed with anti-p-AKT in 71 out
of 103 cases of ALCL, 54 (76%) were positive (Figure 1E).
In the 54 p-AKT positive (p-AKT+) cases, 38 (70%) were
ALK + and 16 (27%) were ALK-. In the 17 p-AKT negativeTable 4 Relationship between the activation status of ALK, AK
ALK p-value p
+ (n = 62) - (n = 41) + (n = 54)
Age (years)
Median 17 48 28
Range 4–68 16–74 0.000* 4–74
Gender
Male 40 27 41
Female 22 14 0.889 13
Symptoms
A 38 26 36
B 24 15 0.828 18
Lesions
Nodal 44 27 42
Extranodal 18 14 0.583 12
Ann Arbor stage
I ~ II 29 21 26
III ~ IV 33 20 0.659 28
*Statistically significant value.
Symptom B, systemic symptoms of fever, night sweats, and weight loss; Symptom A(p-AKT-) cases, 6 (35%) were ALK + and 11 (65%) were
ALK-. Expression of p-AKT was correlated to ALK expres-
sion (×2 = 6.750, p < 0.05). In the 44 ALK + cases studied
with p-AKT staining, 39 (87%) showed activation of AKT.
In the 33 ALK + cases with both cytoplasmic and nuclear
staining, 29 (88%) were p-AKT+ and 4 (12%) were p-AKT-,
and in the 11 cases with cytoplasmic staining only, 10
(91%) were p-AKT + and 1 (9%) was p-AKT-. The expres-
sion of p-AKT had no correlation to the different ALK
expression (p > 0.05; Table 1).Expression of p-mTOR and its correlation to the
expression of ALK and p-AKT
Immunostaining was performed with anti-p-mTOR in
71 cases, 57 (80%) were p-mTOR positive p-mTOR+,
(Figure 1F), of which 39 (68%) were ALK+, and 18 (32%)
were ALK-; 47 (82%) were p-AKT+, and 10 (18%) were
p-AKT-. In the 14 p-mTOR negative (p-mTOR-) cases,
5 (36%) were ALK+, 9 (64%) were ALK-, 7(50%) were
p-AKT+, and 7 (50%) were p-AKT-. Expression of
p-mTOR was correlated to the expression of both ALK
and p-AKT (×2 = 5.102 and 6.501 respectively, p < 0.05).
In the 39 ALK + ALCL cases showing cytoplasmic and
nuclear staining, 30 (91%) were p-mTOR+, and 3 (9%)
were p-mTOR-, and in the 11 ALK + cases showing
cytoplasmic staining only, 9 (82%) were p-mTOR + and
2 (18%) were p-mTOR-. The subcellular ALK expression
patterns had no impact on the expression of p-mTOR in
ALCL (χ2 = 0.619, p > 0.05; Table 2).T and mTOR and the clinical features
-AKT p-value p-mTOR p-value
- (n = 17) + (n = 57) - (n = 14)
29 25 40.5
4–65 0.877 4–74 21–65 0.076
14 44 11
3 0.573 13 3 0.912
11 35 12
6 0.889 22 2 0.068
12 46 8
5 0.547 11 6 0.07
9 28 7
8 0.730 29 7 0.953
, absence of the systemic symptoms.
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Sixty-four out of 71 (90%) ALCL tumors studied were
p-4E-BP1 positive (p-4E-BP1+, Figure 1G), of which 40
(63%) were ALK+, 50 (78%) were p-AKT+, and 56 (88%)
were p-mTOR+. In the 7 p-4E-BP1 negative (p-4E-BP1-)
cases, 4 (57%) were ALK+, 4 (57%) were p-AKT+, and 1
(14%) was p-mTOR+. The expression of p-4E-BP1 had
no correlation to that of ALK and p-AKT (χ2 = 0.783
and 1.359, respectively, p > 0.05), but was closely related
to the expression of p-mTOR (χ2 = 16.531, p < 0.01).
Sixty-six of the 71 (93%) ALCL tumors were p-
p70S6K1 positive (p-p70S6K1+, Figure 1H), of which 42
(64%) were ALK+, 51 (77%) were p-AKT+, and 55 (83%)
were p-mTOR+. In the 5 p-p70S6K1 negative
(p-p70S6K1-) cases, 2 (40%) were ALK+, 3 (60%) were
p-AKT+, and 2 (40%) was p-mTOR+. The expression of
p-p70S6K1 had no correlation to that of ALK and p-AKT
(×2 = 0.119 and 0.684, respectively, p > 0.05), but wasFigure 2 Comparison of overall survival time in ALK + and ALK- ALCL
cumulative survival rate between ALK + and ALK- ALCL patients. (B) Kaplan
between NPM-ALK + ALCLs and those ALCLs with variant ALK fusions.closely related to the expression of p-mTOR (χ2 = 4.295,
p < 0.05; Table 3).
The interrelationship between the expression of ALK,
p-AKT and p-mTOR and the clinical features
The median age of the 62 ALK + ALCL patients was 17
(4 ~ 68) years compared with 48 (16 ~ 74) years for the
41 ALK- cases. The age of onset was much younger in
ALK + patients compared with ALK- cases (p < 0.01). In
ALK + patients, 40 (65%) were male and 22 (35%) were
female. In the 41 ALK- cases, 27 (66%) were male and
14 (34%) were female. Twenty-four (39%) of the ALK +
patients had B symptoms compared with 14 (41%) of the
ALK- cases. Fort-four (71%) ALK + patients had the pri-
mary lesion within the lymph node compared with 27
(66%) ALK- cases. Thirty-three (53%) ALK + patients
were staging at III ~ IV compared with 20 (49%) ALK-
cases. However, there were no statistical differences inpatients. (A) Kaplan-Meier curves showing significant difference in
-Meier curves showing no difference in cumulative survival rate
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tumor, and Ann Arbor staging between ALK + and ALK-
patients (p > 0.05).
The median age of the p-AKT + patients was 28 (4 ~ 74)
years compared with 29 (4 ~ 65) years for the p-AKT-
cases. In the 54 p-AKT + patients, 41 (76%) were male
and 14 (24%) were female. In the 17 p-AKT- cases, 11
(82%) were male and 6 (18%) were female. Eighteen of the
54 (33%) p-AKT + patients had B symptoms compared
with 6 of the 17 (36%) patients with p-AKT- tumors.
Forty-two (78%) p-AKT + patients had the primary lesion
within the lymph node compared with 12 (71%) p-AKT-
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Figure 3 Overexpression of NPM-ALK in BaF3 cells induced their cyto
treatment. (A) NPM-ALK confers IL-3-independent growth to BaF3 cells. St
growth in the presence or absence of IL-3, together with empty vector-con
trypan blue at 24-hour intervals, with each point being the average of the
became resistant to GCs and could survive well in 1 μM Dex, while BaF3 ce
this concentration.at III ~ IV compared with 8 (47%) p-AKT- cases. There
were no statistical differences in the age of onset, sex dis-
tribution, clinical symptoms, primary lesion of the tumor,
and Ann Arbor staging between p-AKT + and p-AKT- pa-
tients (p > 0.05).
The median age of the 57 p-mTOR + patients was 25
(4 ~ 74) years compared with 40.5 (21 ~ 65) years of the
14 p-mTOR- cases. In the p-mTOR + patients, 44 (77%)
were male and 13 (23%) were female, while in the 14
p-mTOR- cases, 11 (79%) were male and 6 (21%) were
female. Twenty-two of the 57 (39%) p-mTOR + patients
had B symptoms compared with 2 of the 14 (14%) pa-
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kine independent growth and resistance to dexamethasone
ably transfected BaF3 cells expressing NPM-ALK were assessed for
taining cells. Viable cell counts were performed in triplicate using
triplicate measurements. (B) BaF3 cells transformed by NPM-ALK
lls transfected with empty vector could not proliferate at
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compared with 8 (57%) p-mTOR- cases. Twenty-nine
(51%) p-mTOR + patients were staging at III ~ IV com-
pared with 7 (50%) p-mTOR- patients. Again, there was
no statistical difference in the age of onset, sex distribu-
tion, clinical symptoms, primary lesion of the tumor, and
Ann Arbor staging between p-mTOR + and p-mTOR-
patients (p > 0.05).
On the whole, except that ALK + ALCL was predom-
inantly seen at a younger age, there was no correlation
between the expression of ALK, p-AKT, p-mTOR and
its two downstream molecules, p-4E-BP1 and p-70S6K1,
and the risk factors of the age of onset, sex distribution,
clinical B symptoms, primary lesion of the tumor, and
the Ann Arbor stage of the disease (Table 4).Karpas 299   BaF3/     BaF3
NPM-ALK   +IL3
p-p70S6K
p-4E-BP1The prognostic significance of the expression of ALK,
p-AKT, p-mTOR, p-4E-BP1, and p-p70S6K1
Follow-up study was carried out in 70 of the 103 (68%)
patients. The follow-up time was from 0.3 to 96.0 months.
The survival time for ALK + patients ranged from 0.6 to
96.0 months and the median time was 27.0 months, with
an expected 5-year survival rate of over 67%. The survival
time for ALK- patients ranged from 0.3 ~ 28.0 months,
with the median time of 4.0 months and a 2-year survival
rate of 20%. The prognosis of ALK + patients was much
better than that of ALK- cases. The difference was stati-
stically significant (p < 0.01, Figure 2A), but there was no
difference in the cumulative survival rate between NPM-
ALK +ALCL patients and those with variant ALK fusions
(Figure 2B). Compared with ALK expression, neither the
expression of p-AKT, p-mTOR, p-4E-BP1, nor p-p70S6K1
had statistically significant differences regarding the
median survival time and the 5-year survival rate in
the ALCL patients.
Among other risk factors, including sex, age, primary
lesion of the tumor (nodal or extranodal), Ann Arbor sta-
ging, histology, B symptoms, and immunological pheno-
type, only B symptoms had prognostic significance. By
using Cox proportional hazards model analysis, only the
expression of ALK and B symptoms had statistical signifi-
cance on the prognosis (p < 0.05), of which the former had
a greater impact than the latter.AKT
p-AKT
GAPDH
Figure 4 Overexpression of NPM-ALK activated the AKT/mTOR
pathway. Overexpression of NPM-ALK in BaF3 cells induced hyper-
activation of the AKT/mTOR pathway, as demonstrated by
hyperphosphorylation of AKT and downstream molecules of mTOR:
4E-BP1 and p70SK6.Overexpression of NPM-ALK activated the AKT/mTOR
pathway in BaF3 cells and induced drug resistance to Dex
and targeting AKT/mTOR re-sensitized the cell to Dex
treatment
Expression of NPM-ALK converted BaF3 cells from IL-3
dependent to cytokine-independent growth, indicating a
strong transforming activity of the kinase (Figure 3A).
Interestingly, expression of NPM-ALK also conferred re-
sistance to GC treatment. Compared with BaF3 cellstransfected with empty vector, the transformed cells
grew well at 1 μM Dex (Figure 3B) and could even sur-
vive at a concentration of Dex as high as 500 μM (data
not shown). Western blotting analysis indicated the
overexpression of NPM-ALK induced hyper-activation
of the AKT/mTOR pathway in BaF3 cells, as demon-
strated by hyperphosphorylation of AKT and down-
stream molecules of mTOR: 4E-BP1 and p70SK6
(Figure 4). Both Dex and the dual PI3K/mTOR inhibitor,
NVP-BEZ235, had little effect on cell growth, but when
they were used in combination a strong synergistic in-
hibitory effect was produced in ALK + cells, especially in
the NPM-ALK transformed BaF3 cells (Figure 5A).
Interestingly, when the kinase inhibitor was used in
combination with Dex, it triggered apoptosis and con-
vert the transformed BaF3/NPM-ALK cells re-sensitive
to GC treatment (Figure 5B). The similar result was
achieved when mTOR inhibitor rapamycin was used
(data not shown).
Discussion and conclusions
Anaplastic lymphoma kinase was first discovered by Dr.
Morris and colleagues in 1994 due to its involvement in
the t(2;5) chromosomal translocation in ALCL [24].
Since ALK expression is normally restricted to neural
tissues, immunostainning of ALCL with ALK-specific
antibodies becomes a quick, convenient, and also a reli-
able means to identify ALK + tumors. Large clinico-
pathologic studies of ALCL have shown that about 80%
of cases of ALK + ALCL exhibit cytoplasmic and nuclear
staining indicative of the presence of NPM-ALK;
whereas the remaining 20% express ALK proteins only
in the cytoplasm of the tumor cells, indicating variant-
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Figure 5 Targeting AKT/mTOR had a therapeutic significance on ALK + tumor cells. (A) Synergistic growth inhibition between the dual
PI3K/mTOR inhibitor, NVP-BEZ235, and Dex in all cells, especially in BaF3/NPM-ALK. (B) A higher apoptosis rate in cells treated with NVP-BEZ235
and Dex together compared with single use of the drugs.
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demonstrated a NPM-ALK staining pattern and 21%
showed the staining pattern of variant-ALK fusions,
which correlated well to the results in the literature
[13,25,26]. We did not find any correlation between
ALK expression and the histological subtype. In regard
to the prognosis, there was no statistical difference be-
tween the patients with NPM-ALK and variant-ALK fu-
sions. These data suggest that ALK + ALCLs have the
same pathogenesis no matter what kind of ALK fusion
partners they have.
The mean age of the 62 patients with ALK + ALCLs
was 25 ± 15 years compared with 46 ± 17 years for the
41 ALK- cases. The former was much younger than the
latter, p < 0.05. Although in our case there was a higherpercentage of patients who had B symptoms and the pri-
mary lesion within the lymph nodes, or had the diseases
at stage III ~ IV in ALK + than ALK- ALCLs, there was
no statistical significance, p > 0.05. However, follow-up
study indicated that ALK + ALCL patients had a much
better prognosis than that of ALK- cases. The 5-year
survival rate of ALK + cases was over 60%, whereas the
2-year survival rate for ALK- cases was only 20%. Kaplan-
Meier curve and log-rank test showed that ALK +ALCL
patients had a significantly better cumulative survival than
ALK- ALCL cases (p < 0.05). This result is much corrobo-
rated by case studies elsewhere [13-16,26], except for the
survival time. In our study the overall 5-year survival rate
was 52% for all ALCL patients, 67% for ALK + cases, and
less than 20% for ALK- patients compared with 77% for
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http://www.biomedcentral.com/1471-2407/13/471the total ALCLs, 80% for ALK +ALCLs, and 40% for
ALK- ALCLs reported [7,8,25-27]. The cause for this dif-
ference is now under investigation.
Compiling evidence demonstrates that oncogenic NPM-
ALK kinase induces the activation of mTOR signaling
pathway, which contributes to NPM-ALK/PI3K/AKT-me-
diated tumorigenesis in ALCL, and that inhibition of
AKT/mTOR represents a potential therapeutic strategy in
ALK +ALCL [9,10,28]. In this study, activation of ALK/
AKT/mTOR pathway was checked in 71 out of the 103
ALCL patient tumor samples. We found that the AKT/
mTOR pathway was highly activated in ALK +ALCL.
Phosphorylation of Thr308p-AKT and Ser2448p-mTOR
was detected at higher percentages in ALK + ALCL tu-
mors and their activation was closely related to ALK ex-
pression, but not related to its expression pattern,
suggesting that no matter what the ALK fusions they
are, they can activate the AKT/mTOR pathway. Our
in vitro study also confirmed that NPM-ALK had strong
transforming activity in lymphocytes and overexpres-
sion of NPM-ALK could induce the activation of the
AKT/mTOR signaling pathway.
Activation of the AKT/mTOR pathway has been associ-
ated with aggressive disease and poor prognosis in certain
cancers, like breast cancer [29-33]. However, currently
there is little information on the prognostic value of the ac-
tivation of the AKT/mTOR pathway in ALCL. We checked
the phosphorylation status of AKT, mTOR, and its two
downstream effectors, p70S6K1 and 4E-BP1, and studied
its correlation with clinical risk factors. Compared with
ALK expression, expression of p-AKT, p-mTOR, p-p70S6K1
and p-4E-BP1 had no correlation with clinical features
such as age, sex, symptoms, primary lesions and tumor sta-
ging, or overall survival, indicating that activation of the
AKT/mTOR pathway had no prognostic value in ALCL.
However, our in vitro study indicated that inhibition of the
AKT/mTOR pathway could effectively reverse the GC re-
sistance induced by overexpression of NPM-ALK in lym-
phocytes. Considering GC is the most commonly used and
highly effective drug used for decades in the treatment of
lymphoid malignancies, targeting AKT/mTOR might be
an attractive therapeutic goal in the future.
In summary, we have shown that the AKT/mTOR
pathway was highly activated in ALK + ALCL. However,
activation of this pathway does not confer any prognostic
significance in ALCL as in some other tumors [34-37].
However, this does not compromise the therapeutic im-
portance of blocking the AKT/mTOR pathway in this dis-
ease considering that activation of AKT/mTOR leads to
resistance to chemo-reagents [38] and glucocorticoids
[39] which constitute the first choice for the treatment of
lymphoid malignancies including ALCL. Clinical use of
AKT/mTOR inhibitors in the treatment of ALCL should
be further explored.Abbreviations
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